Company Overview

For personal use only Results IHL-42X Conclusions 01. Data from phase 2 proof of concept clinical trial supports the potential of IHL-42X as an effective and well tolerated treatment for OSA, meeting the unmet needs of millions of people. 02. IHL-42X reduced AHI, improved sleep quality with respect to both patient reported outcome and actigraphy, and did not lead to any adverse events beyond those expected based on what was expected from dronabinol and acetazolamide. Incannex 03. Low dose IHL-42X was the most effective of the doses tested in this study. - - It reduced AHI by over half (on average) in trial participants and 25% of participants saw an 80% reduction in AHI. Low dose IHL-42X has the lowest number of reported adverse events, even lower than placebo. Low observed THC blood concentration amongst participants below limits for impairment to drive. Lead Assets 0000000000 04. Patent application for IHL-42X considered "novel and inventive" by international patent examiner. 05. Pre-IND meeting completed with FDA and the next major development milestone for IHL-42X will be the commencement of the IND opening clinical trial. Investor Presentation 19

View entire presentation